Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Steglatro (ertugliflozin) is an oral diabetes medicine that helps control blood sugar levels. Ertugliflozin works by helping the kidneys get rid of glucose from your bloodstream.
Steglatro is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Steglatro is not for treating type 1 diabetes.
You should not use Steglatro if you have severe kidney disease or if you are on dialysis.
Ertugliflozin may increase your risk of lower leg amputation, especially if you have had a prior amputation, a foot ulcer, heart disease, circulation problems, or nerve damage.
Steglatro can cause serious infections in the penis or vagina. Get medical help right away if you have burning, itching, odor, discharge, pain, tenderness, redness or swelling of the genital or rectal area, fever, or if you don't feel well.
You should not use Steglatro if you are allergic to ertugliflozin, or if you have:
severe kidney disease (or if you are on dialysis).
Steglatro may increase your risk of lower leg amputation, especially if you have had a prior amputation, a foot ulcer, heart disease, circulation problems, or nerve damage.
To make sure Steglatro is safe for you, tell your doctor if you have ever had:
heart problems;
a diabetic foot ulcer or amputation;
circulation problems or nerve problems in your legs or feet;
liver or kidney disease;
bladder infections or other urination problems;
low blood pressure;
diabetic ketoacidosis;
problems with your pancreas, including surgery;
if you drink alcohol often; or
if you are on a low salt diet.
Follow your doctor's instructions about using Steglatro if you are pregnant. Blood sugar control is very important during pregnancy, and your dose needs may be different during each trimester.
You should not use ertugliflozin during the second or third trimester of pregnancy.
You should not breast-feed while using this medicine.
Steglatro is not approved for use by anyone younger than 18 years old.
Steglatro is usually taken once per day in the morning. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.
You may take Steglatro with or without food.
Call your doctor if you are sick with vomiting or diarrhea, if you consume less food or fluid than usual, or if you are sweating more than usual.
Your blood sugar will need to be checked often, and you may also need to test the level of ketones your urine. Steglatro can cause life-threatening ketoacidosis (too much acid in the blood). Even if your blood sugar is normal, contact your doctor if a urine test shows that you have ketones in the urine.
Low blood sugar (hypoglycemia) can happen to everyone who has diabetes. Symptoms include headache, hunger, sweating, irritability, dizziness, nausea, fast heart rate, and feeling anxious or shaky. To quickly treat low blood sugar, always keep a fast-acting source of sugar with you such as fruit juice, hard candy, crackers, raisins, or non-diet soda.
Your doctor can prescribe a glucagon emergency injection kit to use in case you have severe hypoglycemia and cannot eat or drink. Be sure your family and close friends know how to give you this injection in an emergency.
Also watch for signs of high blood sugar (hyperglycemia) such as increased thirst or urination, blurred vision, headache, and tiredness.
Blood sugar levels can be affected by stress, illness, surgery, exercise, alcohol use, or skipping meals. Ask your doctor before changing your dose or medication schedule.
This medicine can affect the results of certain medical tests. Tell any doctor who treats you that you are using ertugliflozin.
Steglatro is only part of a treatment program that may also include diet, exercise, weight control, regular blood sugar testing, and special medical care. Follow your doctor's instructions very closely.
Store at room temperature away from moisture and heat. Keep unused tablets in the foil blister pack in its original container.
Usual Adult Dose for Diabetes Type 2:
Initial dose: 5 mg orally once a day in the morning
-May increase to 15 mg orally once a day for patients tolerating therapy and requiring additional glycemic control
Maximum dose: 15 mg per day
Comments:
-Volume depletion should be corrected prior to initiating therapy.
-This drug is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Use: An adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.
Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Avoid getting up too fast from a sitting or lying position, or you may feel dizzy.
Get emergency medical help if you have signs of an allergic reaction to Steglatro: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Seek medical attention right away if you have signs of a genital infection (penis or vagina): burning, itching, odor, discharge, pain, tenderness, redness or swelling of the genital or rectal area, fever, not feeling well. These symptoms may get worse quickly.
Call your doctor at once if you have:
new pain, tenderness, sores, ulcers, or infections in your legs or feet;
little or no urination;
ketoacidosis (too much acid in the blood) - nausea, vomiting, stomach pain, confusion, unusual drowsiness, or trouble breathing;
dehydration symptoms - dizziness, weakness, feeling light-headed (like you might pass out); or
signs of a bladder infection - pain or burning when you urinate, increased urination, blood in your urine, fever, pain in your pelvis or back.
Some side effects may be more likely to occur in older adults.
Common Steglatro side effects may include:
genital yeast infections; or
urinating more than usual.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
When you start or stop taking Steglatro, your doctor may need to adjust the doses of any other diabetes medicines you use on a regular basis.
Other drugs may interact with ertugliflozin, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Steglatro only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Steglatro (www.drugs.com/steglatro.html).
Note: This document contains side effect information about ertugliflozin. Some of the dosage forms listed on this page may not apply to the brand name Steglatro.
Applies to ertugliflozin: oral tablet
Along with its needed effects, ertugliflozin (the active ingredient contained in Steglatro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking ertugliflozin:
More common
Less common
Rare
Some side effects of ertugliflozin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Applies to ertugliflozin: oral tablet
The most commonly reported adverse events have included genital mycotic infections, more common in females, but also occurring in males.
Very common (10% or more): Female genital mycotic infections (up to 12.2%)
Common (1% to 10%): Male genital mycotic infections, urinary tract infections, vaginal pruritus, increased urination
Frequency not reported: Pyelonephritis
SGLT2 Inhibitors:
Postmarketing reports: Serious urinary tract infections including urosepsis and pyelonephritis, Fournier's gangrene
Female genital mycotic infections include genital candidiasis, genital infection fungal, vaginal infection, vulvitis, vulvovaginal candidiasis, vulvovaginal mycotic infection, and vulvovaginitis. Male genital mycotic infections balanitis candida, balanoposthitis, genital infection, and genital infection fungal. Urinary tract infections include cystitis, dysuria, streptococcal urinary tract infection, urethritis, urinary tract infection. Vaginal pruritus includes vulvovaginal pruritus and pruritus genital. Increased urination includes pollakiuria, micturition urgency, polyuria, urine output increased, and nocturia.
In the 5 years (2013 to 2018) since SGLT2 inhibitor approval, 12 cases of Fournier's gangrene have been reported. Reports were almost equal in men and women (men=7; women=5), ages ranged from 38 to 78 years, and the average time to onset after starting an SGLT2 inhibitor was 9.2 months (range 7 days to 25 months). All SGLT2 inhibitor drugs except ertugliflozin were included in the reports. Ertugliflozin being the most recently approved agent, is expected to have the same risk, but insufficient patient use to assess risk. All patients were hospitalized, all required surgery, all required surgical debridement, 5 required more than 1 surgery and 1 required skin grafting. Four cases were complicated by diabetic ketoacidosis, acute kidney injury, and septic shock, leading to prolonged hospitalization, and death in 1 case. In the general population, Fournier's gangrene occurs in about 1.6 out of 100,000 males annually, with the highest incidence in men 50 to 79 years. Since diabetes is a risk factor for Fournier's gangrene, a review of the FAERS database for the last 34 years was done and only 6 cases (all males, median age 57 years) were found with several other classes of antidiabetic drugs. Findings with SGLT2 inhibitors appear to show an association over a shorter time frame and involve both males and females.
Nontraumatic lower limb amputation was reported in 3 (0.2%) patients receiving 5 mg and 8 patients (0.5%) receiving 15 mg; there was 1 report (0.1%) in the comparator group. A causal association between this drug and lower limb amputation has not been definitively established.
Common (1% to 10%): Back pain
Uncommon (0.1% to 1%): Nontraumatic lower limb amputation
Very common (10% or more): Hypoglycemia (in combination with insulin and/or insulin secretagogue in patients with moderate renal impairment; up to 27%)
Common (1% to 10%): Decreased weight, hypoglycemia
Rare (0.01% to 0.1%): Ketoacidosis
Frequency not reported: Increases in low-density lipoprotein cholesterol (LDL-C), increased serum phosphate
Ketoacidosis was reported in 3 of 3409 (0.1%) patients treated with this drug during clinical trials; no cases were identified in comparator-treated patients. Mean increases in low-density lipoprotein cholesterol (LDL-C) relative to placebo were 2.6% and 5.4%, in the 5 mg and 15 mg groups, respectively.
Renal related adverse reactions included acute kidney injury, renal impairment, acute prerenal failure. The incidence of renal related adverse reactions was 0.6%, 2.5%, and 1.3% in patients receiving placebo, 5 mg, and 15 mg, respectively.
Common (1% to 10%): Renal related adverse reactions
Frequency not reported: Increased serum creatinine, decreased eGFR
SGLT2 Inhibitors:
Postmarketing reports: Acute Kidney Injury
Common (1% to 10%): Headache
Adverse reactions related to volume depletion include dehydration, dizziness, postural, presyncope, syncope, hypotension, and orthostatic hypotension.
Common (1% to 10%): Adverse reactions related to volume depletion
Thirst includes thirst, dry mouth, polydipsia, and dry throat
Common (1% to 10%): Thirst
Common (1% to 10%): Nasopharyngitis
Rare (0.01% to 0.1%): Hemoglobin increased greater than 2 g/dL and above the upper limit of normal
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Steglatro (www.drugs.com/steglatro.html).
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
